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EFFECT OF THE INCREASING USE OF
PIPERACILLIN/TAZOBACTAM ON THE INCIDENCE OF
VANCOMYCIN-RESISTANT ENTEROCOCCI IN FOUR
ACADEMIC MEDICAL CENTERS
Usha Stiefel, MD; David L. Paterson, MD; Nicole J. Pultz, BS; Steven M. Gordon, MD; David C. Aron, MD, MS; Curtis J. Donskey, MD
In four published reports, formulary substitution of
beta-lactam/beta-lactamase inhibitor combinations such
as piperacillin/tazobactam and ampicillin/sulbactam for
third-generation cephalosporins was associated with
reductions in vancomycin-resistant enterococci (VRE).1-4
Although these data are intriguing, the premise that such
formulary substitutions may be an effective control mea-
sure for VRE deserves further consideration for several
reasons. First, some of the studies that demonstrated
reductions in VRE had significant methodologic limita-
tions such as concurrent implementation of other infec-
tion control measures.5 Second, the prevalence of VRE in
the United States increased during the period in which
piperacillin/tazobactam came into widespread use, sug-
gesting that many hospitals have had increasing rates of
VRE despite increasing use of piperacillin/tazobactam,
but have not reported these findings. Third, although
piperacillin/tazobactam has sufficient anti-enterococcal
activity to inhibit the establishment of VRE colonization in
mice,6 both piperacillin/tazobactam and ampicillin/sul-
bactam promote persistent overgrowth of VRE in the stool
of mice or patients once colonization has been estab-
lished.7,8 Finally, Paterson et al.9 demonstrated that indi-
vidual patients receiving antibiotic regimens that include
piperacillin/tazobactam frequently acquire VRE coloniza-
tion. We hypothesized that increasing the proportion of
use of beta-lactam antibiotics with relatively enhanced 
(ie, piperacillin/tazobactam, ampicillin/sulbactam, piper-
acillin, and ampicillin) versus minimal (ie, third-genera-
tion cephalosporins and ticarcillin/clavulanate) anti-ente-
rococcal activity has been associated with increasing or
unchanged rates of VRE in some hospitals.
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BACKGROUND: The substitution of piperacillin/tazo-
bactam, ampicillin/sulbactam, or both for third-generation
cephalosporins has been associated with reduced vancomycin-
resistant enterococci (VRE). However, piperacillin/tazobactam
came into widespread use during a period in which the prevalence
of VRE increased. We hypothesized that the increasing use of
piperacillin/tazobactam and other agents with relatively enhanced
anti-enterococcal activity (ie, piperacillin, ampicillin/sulbactam,
and ampicillin) has been associated with increased or unchanged
rates of VRE in some hospitals.
DESIGN: We retrospectively evaluated the correlation
between hospital antibiotic use (defined daily doses per 10,000
patient-days of care) and incidence of stool or non-stool VRE isola-
tion. We assessed whether a high or increasing proportion of use
of beta-lactam agents with relatively enhanced versus minimal (ie,
third-generation cephalosporins and ticarcillin/clavulanate) anti-
enterococcal activity would prevent increased VRE.
SETTING: Four academic medical centers.
RESULTS: With the increasing use of piperacillin/tazobac-
tam, the use of beta-lactam agents with enhanced activity against
enterococci surpassed the combined use of third-generation
cephalosporins and ticarcillin/clavulanate in each hospital. In one
hospital, the incidence of VRE was positively correlated with the use
of piperacillin/tazobactam or beta-lactam agents with enhanced anti-
enterococcal activity (P < .0001). The incidence of VRE rose steadily
in another hospital despite relatively high use of beta-lactam agents
with enhanced versus minimal anti-enterococcal activity. A negative
correlation between VRE and piperacillin/tazobactam or beta-lactam
agents with enhanced anti-enterococcal activity was observed in one
hospital, but this correlation was not statistically significant.
CONCLUSION: Increasing the hospital use of piper-
acillin/tazobactam and other beta-lactams with relatively enhanced
anti-enterococcal activity may not be an effective control measure
for VRE (Infect Control Hosp Epidemiol 2004;25:380-383).
ABSTRACT
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METHODS
A retrospective study was conducted in four Cleveland
teaching hospitals to examine the correlation between hos-
pital antibiotic use and the incidence of VRE. The character-
istics of the hospitals are listed in the table. Two of the hos-
pitals (hospitals 2 and 4) perform active surveillance for VRE
stool colonization by screening stool samples submitted for
Clostridium difficile testing and isolate colonized patients,
whereas the other two hospitals perform no active surveil-
lance but do isolate patients with clinical VRE isolates. 
Data regarding the yearly use of antibiotics from
1993 (or 1996) through 2002 were obtained from pharma-
cy records. Antibiotics included in the analysis were third-
generation cephalosporins (cefotaxime, ceftriaxone,
ceftizoxime, and ceftazidime), cefepime, ticarcillin/
clavulanate, piperacillin/tazobactam, ampicillin/sulbac-
tam, piperacillin, ampicillin, quinolones, clindamycin,
metronidazole, and vancomycin. Antibiotic use was calcu-
lated as defined daily doses per 10,000 patient-days of
care. Data regarding patient-days of care were obtained
from the Ohio Department of Health Annual Hospital
Registration and Planning Report. 
The number of patients from whom cultures of non-
stool specimens (ie, clinical cultures including blood, spu-
tum, urine, wounds, and catheter tips) and stool speci-
mens yielded VRE (excluding Enterococcus gallinarum or
E. casseliflavus) was obtained from the databases of the
microbiology laboratory. Patients with multiple isolates
were included only once in the entire cohort for each cat-
egory of specimen. The incidences of VRE per 10,000
patient-days of care were calculated. 
Data were analyzed using SPSS software (version
10.0; SPSS, Inc., Chicago, IL). To evaluate the correlation
between antibiotic use and VRE, Pearson correlation coef-
ficients were calculated. Piperacillin/tazobactam, ampi-
cillin/sulbactam, piperacillin, and ampicillin were
grouped together because these agents have similar in
vitro anti-enterococcal activity (minimum inhibitory con-
centrations [MICs] of 312.5 to 1,250 µg/mL for Cleveland
VRE isolates).6 Ticarcillin/clavulanate was considered to
be similar to third-generation cephalosporins because it
has minimal anti-enterococcal activity (MICs > 10,000
µg/mL for Cleveland VRE isolates).6
RESULTS
The figure shows the incidences of VRE and select-
ed antibiotic use data. After VRE was first isolated, the
incidence increased for 2 to 5 years in each institution
before leveling off or decreasing. The most rapid rise and
highest peak in the incidence of VRE occurred in hospital
1, which did not perform active surveillance. After
piperacillin/tazobactam became available on formulary,
use of this agent increased rapidly in each hospital.
Between 1997 and 1999, hospital 1 substituted
piperacillin/tazobactam for ticarcillin/clavulanate as the
most commonly used beta-lactam/beta-lactamase
inhibitor combination. 
With the increasing use of piperacillin/tazobactam,
the total use of beta-lactam agents with relatively enhanced
(ie, piperacillin/tazobactam, ampicillin/sulbactam,
piperacillin, and ampicillin) anti-enterococcal activity sur-
passed the combined total use of beta-lactam agents with
minimal (ie, third-generation cephalosporins and ticar-
cillin/clavulanate) anti-enterococcal activity in each hospi-
tal (Figure). In hospital 2, the incidence of stool and non-
stool VRE was positively correlated with the use of
piperacillin/tazobactam and the total use of beta-lactam
agents with relatively enhanced anti-enterococcal activity
(P < .0001 for each correlation). In hospital 3, the incidence
of non-stool VRE was positively correlated with the use of
piperacillin/tazobactam (P = .04) but not the total use of
beta-lactam agents with relatively enhanced anti-enterococ-
cal activity (P = .07). In hospital 4, there was no significant
correlation between non-stool or stool VRE and the use of
piperacillin/tazobactam or total beta-lactam agents with rel-
atively enhanced anti-enterococcal activity (P  .08 for
each comparison); however, the incidence of VRE rose
steadily despite maintenance of a relatively high proportion
of use of beta-lactam agents with enhanced versus minimal
anti-enterococcal activity (ratio, 2.2 to 3.8). In hospital 1, a
decrease in the incidence of non-stool VRE occurred
after piperacillin/tazobactam was substituted for ticar-
cillin/clavulanate, resulting in negative correlations
between non-stool VRE and piperacillin/tazobactam or
beta-lactam agents with enhanced anti-enterococcal activi-
ty, but these correlations were not statistically significant
(P = .54 and .47). 
VRE was positively correlated with the use of clin-
damycin and vancomycin in hospitals 3 and 4 and with the
use of quinolones in hospital 4. No other statistically sig-
nificant correlations were found between VRE and specif-
ic classes of antibiotics. 
DISCUSSION
We found that an increasing proportion of use 
of beta-lactam antibiotics with relatively enhanced 
(ie, piperacillin/tazobactam, ampicillin/sulbactam, piper-
acillin, and ampicillin) versus minimal (ie, third-genera-
tion cephalosporins and ticarcillin/clavulanate) anti-ente-
rococcal activity was not temporally associated with
reductions in the incidence of VRE in 3 of the 4 hospitals.
TABLE
CHARACTERISTICS OF THE FOUR HOSPITALS
VRE VRE
First VRE Contact Organ
Hospital Isolated Surveillance Precautions Transplants
1 1995 - + +
2 1994 + + +
3 1994 - + -
4 1992 + + -
VRE = vancomycin-resistant enterococci.
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In hospital 2, the increasing use of piperacillin/tazobac-
tam and total beta-lactams with enhanced anti-enterococ-
cal activity was temporally correlated with a statistically
significant increase in stool and non-stool VRE (Fig., B).
In hospital 4, a steady rise in VRE occurred despite main-
tenance of a high proportion of use of beta-lactams with
enhanced versus minimal anti-enterococcal activity (Fig.,
D). Although retrospective ecologic studies have many
limitations, our findings suggest that the increasing use of
piperacillin/tazobactam and other agents with relatively
enhanced anti-enterococcal activity may not always be
associated with reductions in VRE. 
Although the correlation was not statistically signif-
icant, the incidence of non-stool VRE decreased in hospi-
tal 1 after piperacillin/tazobactam was substituted for
ticarcillin/clavulanate (Fig., A). Because there were no
concurrent changes in infection control measures, it is
possible that the reduction in VRE could have been attrib-
utable in part to the formulary change. Ticarcillin/clavu-
lanate possesses potent anti-anaerobic activity and mini-
mal anti-enterococcal activity, and thus promotes the
establishment and persistence of VRE colonization in
mice.6,7 Alternatively, the other epidemic curves demon-
strate a similar rise in VRE followed by a plateau or reduc-
tion in incidence; the reduction of VRE in hospital 1 there-
fore could simply be representative of the typical epidem-
ic curve for VRE in Cleveland, with the formulary change
being coincidental. 
Our study has several limitations. We studied only
four academic medical centers in one geographic location.
Additional data from other centers are needed. The retro-
spective, ecologic study design is subject to bias related to
failure to control for non-antimicrobial confounding fac-
tors, fluctuations in the incidence of VRE that represent
the natural history of outbreaks, and failure of group-
level–effect estimates to reflect the biological effect at the
individual-patient level.10 These types of bias also limit the
conclusions that can be drawn from previous studies that
examined the effect of formulary changes on VRE.1-5 Data
were not available regarding compliance with infection
control measures in the study hospitals. Some of the
patients may have acquired VRE in outside hospitals or
nursing homes and, therefore, may have been colonized
on admission. However, of a subset of 51 VRE-colonized
patients from one of the institutions (hospital 4), only 4
(8%) had been admitted to an outside hospital or nursing
FIGURE. Comparison of antibiotic use (defined daily doses [DDD] per 10,000 patient-days of care) and incidence of isolation of vancomycin-resistant ente-
rococci (VRE) from stool and non-stool sites in four academic medical centers in Cleveland, Ohio (A through D, respectively). Antibiotic use data were not
available for hospital 3 in 1997 and 1998. Doc = patient-days of care; solid diamonds = combined use of piperacillin/tazobactam, ampicillin/sulbactam,
piperacillin, and ampicillin; solid triangles = piperacillin/tazobactam; solid squares = total third-generation cephalosporins including ceftazidime, cefo-
taxime, ceftizoxime, and ceftriaxone; solid circles = ticarcillin/clavulanate; open circles = non-stool VRE; and open squares = stool VRE.
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home within the previous 5 years. Although the ratio of
use of beta-lactams with enhanced versus minimal anti-
enterococcal activity rose in each of the hospitals, total
third-generation cephalosporin use did not decrease sig-
nificantly in any of the hospitals. May et al.3 previously
found that the increasing use of piperacillin/tazobactam
was associated with a decrease in the prevalence of VRE
in an intensive care unit that also significantly reduced
third-generation cephalosporin use, but not in 2 similar
units that did not concurrently reduce cephalosporin use.
Because non–beta-lactam classes of antibiotics may pro-
mote VRE, the frequent use of agents such as clindamycin
or vancomycin may result in the maintenance of high
rates of VRE even if beta-lactams with enhanced anti-ente-
rococcal activity inhibit the establishment of colonization.
Efforts to limit the unnecessary use of all classes of antibi-
otics are likely to be most effective in controlling VRE,
and the combination of such efforts with contact precau-
tions has been shown to be effective in reducing rates of
VRE on an oncology unit.11
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